Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

Rhea-AI Summary

Xtant Medical (NYSE American: XTNT) announced the commercial launch of Trivium™ Shaped on May 6, 2026, an extension of the Trivium bone graft portfolio offering pre-shaped, ready-to-use forms (boats and strips) for surgical use.

Trivium Shaped builds on the April 2025 sculptable format, uses PureLoc™ automated DBM milling to produce elongated cortical fibers, and is available through Xtant's nationwide independent agent distribution network.

Positive

• Commercial launch of Trivium Shaped on May 6, 2026
• Provides pre-shaped boats and strips to reduce intraoperative preparation
• PureLoc™ technology produces elongated uniform cortical fibers
• Distributed via Xtant's nationwide independent agent network

Negative

• No sales, pricing, or revenue impact figures disclosed in the announcement

News Market Reaction – XTNT

-0.50%

-0.50% Session close to close

In the May 6 session, XTNT declined 0.50%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends Xtant’s Trivium™ bone graft platform with Trivium™ Shaped, adding pre-shap...

Analysis

This announcement extends Xtant’s Trivium™ bone graft platform with Trivium™ Shaped, adding pre-shaped configurations that aim to improve handling and procedural efficiency. It builds on the sculptable format introduced in April 2025 and highlights PureLoc™ technology within a composite allograft construct. In the context of recent divestitures and a focus on higher-margin biologics, this launch reinforces the company’s emphasis on orthobiologics-driven growth and product breadth.

Key Figures

Trivium sculptable launch: April 2025

1 metrics

Trivium sculptable launch April 2025 Initial launch date of Trivium sculptable bone graft format

Historical Context

5 past events · Latest: Apr 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 13	Distribution agreement	Positive	-0.7%	Exclusive U.S. rights to HEMOBLAST Bellows and salesforce expansion.
Apr 09	Corporate social initiative	Neutral	+1.0%	Support for Threshold of Life donor memorial in Montana.
Mar 31	Earnings results	Positive	+2.8%	Full-year 2025 revenue growth, profitability, and 2026 guidance issued.
Mar 25	Earnings call notice	Neutral	+0.6%	Announcement of timing and access details for Q4/FY 2025 call.
Mar 02	Divestiture payment	Positive	+0.2%	Final Companion Spine payment used partly to reduce term loan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamental and strategic updates have mostly seen modest positive price reactions, with one notable divergence on a seemingly constructive distribution deal.

Recent Company History

Over the last several months, Xtant has focused on portfolio reshaping and biologics growth. In 2025, it returned to profitability with $133.9M revenue and a $5.0M net income, supported by divestitures totaling $21.4M. A March 2026 8-K detailed cash strengthening and 2026 revenue guidance of $95M–$99M. Subsequent news covered finalization of Companion Spine payments and a new HEMOBLAST® distribution deal. Today’s Trivium™ Shaped launch fits this orthobiologics-focused product expansion trajectory.

Key Terms

composite allograft, cortical fibers, cancellous bone, demineralized bone matrix (DBM), +2 more

6 terms

composite allograft medical

"Trivium is a composite allograft that combines cortical fibers..."

A composite allograft is a surgical transplant that moves a package of different tissues — such as skin, muscle, bone, nerves and blood vessels — from a donor to replace or rebuild a complex body part like a hand or face. For investors, it matters because these procedures involve specialized surgical techniques, strict regulatory oversight, long-term patient follow-up and unique supply and reimbursement challenges, similar to replacing an entire multi-part machine rather than a single component.

cortical fibers medical

"combines cortical fibers, cancellous bone, and demineralized bone matrix..."

Cortical fibers are the bundles of nerve-cell extensions in the brain’s outer layer (the cortex) that carry electrical signals between neurons and across regions, much like insulated wires linking parts of an electrical panel. Their condition influences thinking, memory and movement, so changes seen in imaging or clinical tests can signal whether a drug, device or diagnostic is likely to help or fail; that prospective impact affects the commercial and regulatory outlook for neurological treatments.

cancellous bone medical

"combines cortical fibers, cancellous bone, and demineralized bone matrix..."

Cancellous bone is the lightweight, sponge‑like inner layer of bone that looks and behaves like a honeycomb, providing structural support while housing bone marrow and blood vessels. For investors, its condition and healing capacity drive demand for products and services such as orthopedic implants, joint‑replacement techniques, fracture treatments, imaging tools and drugs for bone diseases, because poor cancellous bone increases complication rates and market opportunity for remedies.

demineralized bone matrix (DBM) medical

"and demineralized bone matrix (DBM) into a single, connected graft matrix."

Demineralized bone matrix (DBM) is donor bone that has been processed to remove its hard mineral content, leaving a soft collagen scaffold rich in natural proteins that help stimulate new bone growth. Think of it like a compost-rich seedbed that encourages seeds to sprout: surgeons place DBM where bone needs to heal or fuse. Investors track DBM because its safety, regulatory approval, manufacturing quality, and surgeon adoption affect sales, competitive positioning, and reimbursement in the orthopedic and spine markets.

orthobiologics medical

"Trivium Shaped joins our growing line of orthobiologics innovations..."

Orthobiologics are medical products made from natural biological materials—such as concentrated blood components, cellular therapies, or processed bone and tissue—used to help muscles, bones, tendons and ligaments heal faster or more effectively. For investors, these products matter because clinical evidence, regulatory approval, and insurance coverage drive adoption and revenue potential much like how a new, better tool can win market share in a crowded toolbox.

bone graft medical

"extension of its Trivium bone graft portfolio that is now available..."

A bone graft is a surgical procedure that places natural or synthetic material into a damaged or missing bone area to provide a scaffold that helps the body rebuild bone and restore strength. For investors, bone grafts are important because they drive sales of implants, biologic materials and surgical tools, and are sensitive to clinical outcomes, regulatory approvals and reimbursement—factors that affect companies’ revenue and growth prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft portfolio that is now available in pre‑shaped configurations designed to support handling, preparation, and placement across a range of surgical applications.

Trivium Shaped builds on the success of the Trivium sculptable format (launched in April 2025)  by offering surgeons ready-to-use graft forms, including boats and strips, designed to enhance consistency and handling in the operating room. The introduction of pre-shaped configurations represents a significant advancement in graft convenience and clinical utility, allowing surgeons to optimize surgical workflow while maintaining the exceptional performance characteristics of the Trivium platform.

"The launch of Trivium Shaped reflects our commitment to providing surgeons with versatile, high-performance solutions that address their diverse needs," said Sean Browne, President and CEO of Xtant Medical. "By combining the proven benefits of our advanced bone graft technology with ready-to-use pre-shaped formats, we're enabling surgeons to achieve consistent, reliable outcomes with reduced preparation time and greater efficiency. Trivium Shaped joins our growing line of orthobiologics innovations for which we are known."

Trivium is a composite allograft that combines cortical fibers, cancellous bone, and demineralized bone matrix (DBM) into a single, connected graft matrix. The Trivium Shaped launch highlights the use of PureLoc™ technology, a proprietary automated DBM milling process that produces elongated, uniform cortical fibers that form the structural foundation of the graft.

Trivium™ Shaped is now available to Xtant Medical's nationwide distribution network of independent agents.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the benefits and performance of Trivium™ Shaped and its potential to enable surgeons to achieve consistent, reliable outcomes with reduced preparation time and greater efficiency. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of Trivium™ Shaped and other new products to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients; the ability of the Company and its sales personnel and distributors to successfully sell Trivium™ Shaped, the Company's ability to successfully manufacture Trivium™ Shaped and in amounts required to meet demand; the Company's ability to continue to innovate, develop and introduce new products and the success of those products; the performance and success of the Company's fully vertically integrated structure; the Company's ability to engage and retain new and existing independent distributors, agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the Company's future operating and financial performance and its ability to increase or maintain revenue; and other risk factors, including in particular those associated with the launch of new products, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 31, 2026 and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-expands-trivium-portfolio-with-the-commercial-launch-of-trivium-shaped-302763740.html

SOURCE Xtant Medical Holdings, Inc.

FAQ

What is Trivium Shaped and when did XTNT launch it?

Trivium Shaped is a pre-shaped extension of the Trivium bone graft portfolio; it launched on May 6, 2026. According to the company, it offers ready-to-use boats and strips designed to improve handling and reduce preparation time in surgery.

How does Trivium Shaped differ from the April 2025 Trivium sculptable format (XTNT)?

Trivium Shaped provides pre-formed grafts like boats and strips, unlike the sculptable format introduced in April 2025. According to the company, the pre-shaped forms aim to increase consistency and streamline surgical workflow.

What technology underpins Trivium Shaped and why does it matter for surgeons?

Trivium Shaped uses PureLoc™ automated DBM milling to create elongated, uniform cortical fibers. According to the company, this forms a structural graft foundation intended to maintain Trivium's performance while improving handling.

Is Trivium Shaped available nationwide for hospitals and surgeons (XTNT)?

Yes. According to the company, Trivium Shaped is now available through Xtant Medical's nationwide distribution network of independent agents, enabling broad commercial access across the U.S.

Did Xtant disclose sales or clinical outcome data for Trivium Shaped (XTNT)?

No sales or specific clinical outcome figures were provided in the announcement. According to the company, the launch emphasizes handling and preparation benefits but does not include revenue or trial-readout data.